Automation of testing operations, regional laboratory expansion and faster turnaround

「Under the Service Level Enhancement initiative, we completed the regional decentralization of bacteriology and pathological cytology testing, for which rapid result reporting is required, and are working to improve services.」

「Under “building next-generation laboratories,” the new testing building at BML Food Science, Phase 6 of the BML General Research Institute building, and the new Tokyo laboratory of PCL Japan became operational. This will enable sustainable expansion of testing capacity for the next 10 years.」

「Under the Next-Generation Laboratory Development initiative, the new testing building at BMLフード・サイエンス began operations in May 2024, followed by the new building at BML総合研究所 and the new Tokyo laboratory of ピーシーエルジャパン in January 2025. This will enable sustainable expansion of testing capacity for the next 10 years.」

「Under the Next-Generation Laboratory Development initiative, we are currently constructing the sixth-phase building at BML総合研究所, the new Tokyo laboratory of ピーシーエルジャパン, and a new building at BMLフード・サイエンス. This will enable sustainable expansion of testing capacity for the next 10 years.」

「Capital investment during the consolidated fiscal year amounted to ¥7,968 million. The main investments were in testing equipment, including automated analyzers.」

「We also conduct five-specimen pooled PCR testing to meet large volumes of requests for infection screening of asymptomatic individuals. Our pooled testing eliminates manual work and uses a specially configured, high-performance liquid handler, enabling us to process more than 10,000 specimens per day.」

「For novel coronavirus (SARS-CoV-2) PCR testing, we introduced 5 Amplitude automated PCR testing platforms capable of processing multiple specimens, expanding our testing outsourcing operations. As a result, BML総合研究所 alone has maintained testing capacity of more than 30,000 tests per day to date.」

「For novel coronavirus (SARS-CoV-2) PCR testing, we had already introduced 2 automated PCR testing platforms capable of processing multiple specimens in December 2020. We subsequently added 1 unit in March 2021 and began operating it in April, then added a further 2 units in June, progressively expanding our testing outsourcing operations. As a result, BML総合研究所 alone acquired testing capacity of more than 30,000 tests per day.」

「For novel coronavirus (SARS-CoV-2) PCR testing, we have progressively expanded our testing outsourcing operations in response to requests from the authorities. Following the introduction and launch of a new automated PCR testing platform in December 2020, BML総合研究所 acquired testing capacity of more than 15,000 tests per day. As a result, the Group as a whole became capable of processing more than 20,000 outsourced tests per day. We will continue introducing large-scale testing equipment to further strengthen our testing outsourcing operations.」

「For novel coronavirus (SARS-CoV-2) PCR testing, we promptly expanded our testing outsourcing operations in response to requests from the authorities and were able to substantially increase the number of specimens processed per day. Because this PCR testing required us to independently establish a testing line using research-use reagents, our accumulated expertise was fully utilized to increase processing capacity efficiently and with a high degree of accuracy. We are now able to process nearly 4,000 specimens per day and plan to further increase capacity.」

「Capital investment during the consolidated fiscal year amounted to ¥5,630 million. The main investments were in testing equipment, including automated analyzers, and software.」

「Regarding our testing outsourcing operations, at BML総合研究所, our main laboratory, we will continue developing new testing methods using next-generation sequencers and mass spectrometers, while pursuing further automation in fields including bacteriology testing. At our regional full-service laboratories, we will expand the range of tests to improve user services and accelerate result reporting.」

「In the clinical testing business, we strengthened coordination between our laboratories and headquarters, sought to develop the hospital and clinic markets, pursued solution-based sales to large facilities, conducted in-depth sales activities such as expanding sales of priority testing items to existing users, and implemented a laboratory utilization strategy using regional and separate laboratories to expand business performance. As a result, revenue from the clinical testing business increased 2.0% year on year.」

「In the clinical testing business, we strengthened coordination between our operating sites and headquarters, sought to develop the hospital and clinic markets, and expanded our business through proposal-based sales using the FMS/branch laboratory model for large facilities, in-depth sales to existing users, including the expansion of priority tests, and a laboratory utilization strategy using regional and specialized laboratories.」

「In the clinical testing business, we strengthened coordination between our operating sites and headquarters, sought to develop the hospital and clinic markets, and expanded our business through proposal-based sales using the FMS/branch laboratory model for large facilities, in-depth sales to existing users, including the expansion of priority tests, and a laboratory utilization strategy using regional and specialized laboratories.」

「Capital investment during the consolidated fiscal year amounted to ¥5,710 million. The main investments were in testing equipment, including automated analyzers, and software.」

「As part of our efforts to automate testing, we will introduce next-generation equipment in the immunology and bacteriology testing fields. At our regional laboratories, we will expand the range of tests to improve user services and work to accelerate result reporting, while also expanding our specialized laboratories to improve testing quality.」